Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis

Maria J. Fernandez Turizo[1], **Rushad Patell**[2], **Jeffrey I. Zwicker**[3,4]

[1]Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

[2]Division of Medical Oncology and Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

[3]Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY

[4]Weil Cornell Medical College, New York, NY, United States

Abstract

Comprehensive protein analyses of plasma are made possible by high-throughput proteomic screens, which may help find new therapeutic targets and diagnostic biomarkers. Patients with cancer are frequently affected by venous thromboembolism (VTE). The limited predictive accuracy of current VTE risk assessment tools highlights the need for new, more targeted biomarkers. Although coagulation biomarkers for the diagnosis, prognosis, and treatment of VTE have been investigated, none of them have the necessary clinical validation or diagnostic accuracy. Proteomics holds the potential to uncover new biomarkers and thrombotic pathways that impact the risk of thrombosis. This review explores the fundamental methods used in proteomics and focuses on particular biomarkers found in VTE and cancer-associated thrombosis.

Keywords

proteomics; thrombosis; cancer-associated thrombosis; biomarkers

Introduction

Venous thromboembolism (VTE) represents a significant global public health issue, impacting roughly 10 million individuals annually worldwide and contributing to over

3 million annual fatalities.[1] Among patients with cancer, thrombotic events are highly prevalent, with active cancer accounting for 20% of the overall incidence of VTE.[1] The annual incidence of VTE in patients with cancer is 5-20% in higher-risk malignancies, compared to 0.1% in the general population.[2] Clinical biomarkers for the diagnosis, risk prediction, recurrence estimation, and response to treatment in cancer-associated thrombosis (CAT) are limited.[3]

D-dimer as a marker of endogenous fibrinolysis, has found utility as a valuable biomarker in clinical practice for the diagnosis of VTE. Nevertheless, it lacks specificity, such that is largely used as a diagnostic assay to exclude VTE, primarily due to its strong negative predictive value.[4] Although various additional biomarkers, including P-selectin, tissue factor (TF), microRNAs, among others, have been investigated, none have been validated sufficiently for routine application in clinical practice.[5,6]

Predicting VTE recurrences continues to pose challenges. D-Dimer in combination with clinical and genetic risk factors has been applied to help predict which patients will develop recurrent VTE following a course of therapeutic anticoagulation. Various studies have indicated that, following an initial spontaneous VTE, patients with low D-Dimer levels have a low risk of VTE recurrence upon discontinuation of anticoagulation.[7,8] Conversely, patients experiencing a provoked VTE with elevated D-Dimer levels after discontinuing anticoagulation therapy, have an increased risk for VTE recurrence.[9,10]

Biomarkers for thrombosis prediction in cancer

Standard cutoffs for D-Dimer have limited specificity, particularly in cancer patients in which D-Dimer levels are often increased at baseline. In cancer patients, higher levels of D-Dimer, above the 75th percentile, have been found to correlate with an increased risk of VTE.[11,12] A rising D-Dimer level over time has also been found to be predictive of VTE in the cancer population.[13] The Khorana score is useful for VTE prediction in ambulatory cancer patients, with a high negative predictive value (>80%). The score incorporates pre-treatment platelet count and leukocyte count, hemoglobin level, cancer type, and body mass index (BMI). The positive predictive value of a higher-risk Khorana score is approximately 10%.[14]

Different models have been developed to improve the accuracy of thrombosis prediction with mixed results, using various cutoffs for D-Dimer, and the addition of biomarkers to the Khorana score.[15–17] The Vienna Cancer and Thrombosis study score added D-Dimer and soluble p-selectin to the Khorana score factors, with an accurate prediction of VTE.[18] The PROTECHT removed BMI from the prediction model and included chemotherapy.[19] Additional prediction models, including ONKOTEV, COMPASS-CAT, Tic-ONCO, and IMPEDE, among others, have attempted to enhance the diagnostic accuracy of VTE in patients with malignancies. These models integrate various factors such as various types of malignancies, cancer stages, genetic risk factors, and D-Dimer levels.[14]

Considering D-Dimer's low positive predictive value, limited specificity, and modest discriminatory ability in cancer patients, there is a need for novel specific biomarkers to more effectively exclude VTE in this population.[20–24] Additionally, traditional clinical VTE

diagnostic assessment tools, such as the Wells' or Geneva scores, show limited efficacy in ruling out VTE in cancer patients. The mere presence of a comorbid malignancy elevates the clinical probability of VTE, requiring imaging for the majority of cancer patients to effectively exclude thrombosis.[15]

Measuring the proteome

Based on the modest diagnostic and predictive accuracy of available coagulation biomarkers in VTE, the question remains whether measurement of other circulating plasma proteins offers clinical benefit. Proteomic screens are promising not only for discovering novel biomarkers for VTE in cancer but also for enhancing our understanding of the underlying pathophysiology of thrombus formation and the complex interplay among various prothrombotic factors, such as chemotherapy, immune response, and underlying malignancies.[25] Various technologies are utilized to measure proteins in tissues, serum, or plasma, including highly optimized single protein assays, mass spectrometry (MS), and affinity-based assays. Below is a summary of proteomic methodologies and observations to date pertaining to VTE.

Mass spectrometry proteomics

MS is a technique used for the identification and quantification of proteins within a sample, allowing for customized measurements of specific targets of interest. It provides valuable insights into the structure, function, and composition of the proteome across diverse biological systems. The process involves ionizing peptides generated by proteolysis, a step accomplished through methods like electrospray ionization, surface-enhanced laser desorption ionization, and matrix-assisted laser desorption ionization. Subsequently, an electric or magnetic field is used to separate the ionized peptides in a mass analyzer, based on their mass-to-charge ratios (m/z). Tandem MS enhances the confidence of peptide identification by using molecules that have undergone prior fragmentation, performing further fragmentation, and isolation in a secondary mass analyzer.[26]

Common combinations of mass analyzers and ionization methods include matrix-assisted laser desorption ionization, and liquid chromatography (LC) coupled with tandem MS. To aid peptide identification, various processes are typically employed, including sample enrichment, fractionation, depletion, and labeling. These methods promote protein separation, enhance detection sensitivity, and facilitate the identification of less abundant plasma proteins. Following peptide identification, specialized software tools and search algorithms are used to identify the parent protein in online databases. To enhance result confidence, statistical methods and secondary proteomics techniques are employed for validation. Furthermore, multiplexed MS allows for the simultaneous analysis of multiple samples in a single measurement, employing various methods such as isobaric labeling or label-free quantification.[27,28]

Various methods deploy MS techniques for proteomic screening, including shotgun proteomics and targeted strategies. Shotgun proteomics, frequently employed in discovery studies, indirectly measures entire proteomes by analyzing peptides produced through the enzymatic breakdown of intact proteins. Analyzing complex samples such as plasma, poses

a particular challenge in shotgun proteomics due to the differential abundance of proteins. In contrast, targeted proteomics approaches provide an alternative to the shotgun method, employing specific ions to identify a predefined set of peptides.[29] Targeted approaches demonstrate high sensitivity, specificity, and reproducibility, proving effective for protein identification in diverse samples, and excluding the need for affinity reagents.[30–32]

MS proteomics offers some advantages in comparison to conventional affinity-based assays (Table 1), such as its high specificity and ability to process large sample volumes. In addition, MS allows for the examination of post-translational modifications and characterization of isoforms, enhancing its versatility in protein analysis.[33,34] On the contrary, limitations of the technique include a constrained ability to detect low abundance proteins in plasma; a limited dynamic range potentially hindering a comprehensive assessment of the proteome. MS encounters difficulties analyzing large, hydrophobic proteins and complex samples. It is also expensive and requires skilled operators and advanced instrumentation. Notably, the throughput capacity of conventional MS is comparatively lower than that of affinity-based assays.[35] This disparity contributes to the weak correlation observed between MS and affinity-based platforms.[30]

Mass spectrometry in venous thromboembolism proteomics

The literature on proteomics techniques for identifying clinical biomarkers in thrombosis is heterogeneous and limited, ranging from the analysis of complex plasma samples to specific protein analyses within distinct cellular subsets.[36] Table 2 summarizes studies focusing on the analysis of plasma samples using proteomics in VTE.

Zhang *et al.* used matrix-assisted laser desorption ionization MS analysis in patients with acute pulmonary embolism (PE) and healthy controls. After validation with ELISA, only haptoglobin was associated with PE.[37] Various studies have associated haptoglobin levels with VTE. It appears that acute PE without pulmonary hypertension induces haptoglobin, but severe PE causes the haptoglobin concentration to decrease in proportion to the severity of the pulmonary hypertension.[38,39]

Han *et al.* profiled proteins from 13 plasma samples using MS and 32 plasma samples using antibody-based-assay proteomics. Samples were obtained from two independent case-control studies of patients with high-risk PE, non-high-risk PE, and healthy controls. Serum amyloid A-1 (SAA1), calprotectin (S100A8), tenascin- C (TNC), gelsolin (GSN), and histidine-rich glycoprotein (HRG), were differentially expressed in patients with PE and or in high-risk PE, in comparison to healthy controls.[40]

Tandem MS has also been used to analyze plasma samples from patients with VTE. Jensen *et al.* found that Transthyretin, vitamin K-dependent protein Z, and protein/nucleic acid deglycase, were associated with incident VTE in a study comparing patients with VTE and healthy controls.[41]

Affinity proteomics

Affinity proteomics employs binding agents to serve as probes for the targeted detection of proteins. Binding agents include antibodies or aptamers, single-stranded DNA or RNA

molecules designed to selectively bind specific targets.[42] Diverse platforms use affinity proteomics for the large-scale study of biomarkers, including antibody-based suspension bead arrays, proximity extension assays, surface arrays, and the aptamer-based Soma Scan assay.[27,43,44] All platforms enable multiplexed profiling of proteins, enabling simultaneous analysis of samples within a single experiment.[45]

Affinity-based assays offer several notable advantages, including a wide dynamic range, multiplexing capability, high specificity that minimizes cross-reactivity with non-target proteins, and versatility across various sample types. Limitations of affinity-based proteomics include alterations between targets and binding agents. For instance, structural and conformational changes in proteins, nonspecific protein binding, missense mutations, single nucleotide polymorphisms, and differential splicing can disturb the interaction between binding epitopes and targets.[43,44,46] Mutations within a gene's coding regions induce alterations in the amino acid sequence of the associated protein. Changes that occur within the epitope target region may significantly impact the protein's binding affinity.[46] To address this issue, various methods have been developed to validate the target of the binding agent.[47]

Antibody-based assays

Proximity extension assays

Proximity extension assays (PEA) use antibodies conjugated with DNA strands, engineered to hybridize after binding to a particular target molecule. This process generates a unique DNA template that can be amplified, detected, and quantified using polymerase chain reaction, enabling the quantification of the target molecule. Olink proteomics offers multiple commercially available PEA panels.[34] PEA methods have also been paired with different genomic technologies such as next-generation sequencing, to increase throughput capacity for proteomic screening.[48]

Proximity extension assays in venous thromboembolism proteomics

The literature on PEA studies in VTE proteomics represents a limited yet evolving landscape, marked by significant variability in methodologies across studies. While some investigations identify specific protein associations with VTE phenotypes, the overall heterogeneity in approaches emphasizes the need for further standardization and larger-scale studies. Below are a few highlighted key studies.

Ten Cate *et al.* identified 5 proteins specifically associated with an isolated PE phenotype, compared with deep vein thrombosis (DVT) or DVT-associated PE phenotypes. Using 5 PEA panels, 3 proteins (interferon-γ, glial cell-line derived neurotrophic factor, and interleukin-15Rα) were found to be differentially expressed in VTE patients.[49] Ligation of the inferior vena cava to induce DVT in mice, demonstrated that intrathrombotic levels of interferon-γ were progressively elevated as the post ligation interval extended.[50] In addition, Interleukin15 complexes have a well-established role in cardiovascular disease, participating in inflammatory pathways and coronary thrombosis.[51]

In the context of DVT, Memon *et al.* employed a single PEA panel to profile proteins in patients with acute DVT and matched controls. The study identified 7 proteins significantly associated with VTE, including p-Selectin, TF pathway inhibitor, Von Willebrand factor (VWF), transferrin receptor protein 1, osteopontin, bleomycin hydrolase, and ST2.[52] P-selectin increases leukocyte and platelet rolling and adhesion, enhances TF expression in monocytes, and instigates the release of procoagulant substances (53). The role of transferrin receptor protein 1, osteopontin, bleomycin hydrolase, and ST2 in thrombosis remains under investigation (54–56).

Bead-based assays

Bead-based assays are antibody-based methods for proteomic screening, involving the immobilization of antibodies into microscopic beads. Each bead is conjugated with an antibody that interacts with proteins from a biological sample and creates complexes that can be quantified. Unique fluorescent labels are often attached to allow the identification of the complexes. Bead-based assays have a high throughput capacity and high multiplexing ability. They have been applied for various purposes, including the detection of cytokines, auto-antibodies, the analysis of monoclonal antibodies, and biological warfare agents.[34]

Bead-based assays in venous thromboembolism proteomics

The VEREMA affinity proteomics study assessed plasma samples using bead arrays obtained from patients with VTE and matched healthy controls. A set of 408 proteins, selected for their known involvement in the coagulation cascade, expression in endothelial cells, and associations with cardiovascular disease and inflammation pathways, served as targets. The findings were then compared to plasma samples from the French FARIVE study for replication, ultimately confirming the independent associations of VWF and platelet-derived growth factor subunit B (PDGFB) with VTE.[57] PDGF is expressed in endothelial cells and platelets, and elevated levels are associated with an increased risk of thrombosis.[58]

Various studies have used bead-based assays to identify biomarkers that are able to distinguish between PE and DVT.

Razzaq *el al.* analyzed plasma samples of patients with VTE from the Marseille Thrombosis Association study (MARTHA) study using a machine learning framework employing an artificial neural network approach to integrate plasma proteomics with genetic data. The MARTHA study involved targeted affinity proteomics using suspension bead assay technologies. PLXNA4 was identified as a new susceptibility locus for PE.[59] PLXNA4 plays an important role in pathways related to thrombosis, stimulating TNF-α and IL-6 production in macrophages.[60] Its ligand SEMA3, is known to promote vascular remodeling and regulate platelet aggregation.[61,62] It has been strongly associated with various lung function markers but its precise association with PE is still under study.[63]

Complement factor H-related 5 (CFHR5) protein represents a potential diagnostic and or risk predictive biomarker for VTE. Suspension bead arrays were used to analyze plasma samples obtained from patients in the VEBIOS study. Elevated levels of CFHR5 were associated with increased thrombin generation and platelet activation *in vitro*.[64] Notably,

the association between CFHR5 and VTE was also reported in a cohort of patients with COVID-19 infection.[65]

Aptamer-based assays

Aptamers are nucleotide-based agents with protein affinity. Large nucleotide sequences are mixed with target peptides or proteins for binding. A commercial platform based on a large library of synthetic oligonucleotide ligands was developed by Somascan. The specificity of the technique can be limited by cross-reactivity among agents. Somascan aptamers are modified with aromatic benzyl side chains to reduce cross-reactivity.[34] Aptamer-based assays have a high sample throughput and multiplexing capacity, with a wide dynamic range, and no toxic or immunogenic potential.[66]

There are limited studies to date evaluating proteins through the Somascan platform and the development of thrombosis.

In a study of 59 critically ill adolescents using data obtained from the Somascan platform, 9 patients developed incident DVT. Higher levels of thrombin-antithrombin complexes and lower levels of factor XIII were associated with DVT. In addition, CD36, macrophage inhibitory cytokine-1, and erythropoietin receptor were marginally associated with DVT.[67]

Comparative analysis of proteomics techniques

Comparing different proteomic platforms such as MS, antibody, and aptamer, affinity-based assays have generally demonstrated limited correlation. Although consistent and comparable outcomes across different platforms are lacking.

The analysis of 173 human blood plasma samples using both MS-based platforms and PEA (Olink), identified 35 proteins common to both techniques. The two MS platforms demonstrated a strong correlation coefficient exceeding 0.5 for 23 of these 35 proteins. However, across all three platforms, including PEA and MS, only 6 out of the 35 proteins exhibited a correlation coefficient exceeding 0.5.[68]

Various investigations have found a weak correlation between PEA (Olink) and the SomaScan platforms.[46,69,70] However, studies have been constrained by a limited number of analyzed proteins and a small sample size. For instance, in a comparative study of 27 healthy individuals and 27 with acute VTE, there was a poor agreement for 8 common coagulation proteins including D-dimer and fibrinogen.[71] In addition, a large-scale plasma proteomics study comparing the United Kingdom Biobank Olink (PEA) and Iceland Somascan platforms, revealed a modest Spearman correlation between both techniques.[72]

Proteomics in cancer-associated thrombosis

CAT exhibits distinctive features that set it apart from other types of VTE, including differences in risk factors, pathophysiology, and management strategies. Central to its pathogenesis is the pivotal role of TF, a key player in cancer progression and CAT.[15] TF induces the activation of platelets and the coagulation cascade. Its release into circulation occurs within TF-positive extracellular vesicles. Notably, certain tumor types, including

pancreatic, ovarian, brain, and cervical cancers, manifest elevated levels of TF, with potential correlations to specific oncogenic gene mutations, angiogenesis, and tumor histological grade.[73,74] Procoagulant proteins such as plasminogen activator inhibitor 1, podoplanin, and protein disulfide isomerase have also been implicated in CAT. Table 3 provides a summary of proteomic plasma biomarkers evaluated in CAT.

Differential proteomic expression in various malignancies

Proteomic investigations include differential protein expression across various malignancies as they relate to CAT. In a study of patients with lung (N=30, 15 with VTE) and pancreatic cancer (N=30, 15 with VTE) using LC-MS, there were distinct differential expression patterns of immunoglobulin-derived proteins and tetranectin in cancer patients with and without VTE. Particularly noteworthy was the absence of overlap between lung and pancreatic cancer, emphasizing the nuanced variations in mechanisms and proteins based on the primary malignancy site.[75] Cancer-derived immunoglobulins are highly expressed in cancer cells and mediate multiple processes in cancer progression, coagulation, and inflammation, including activation of platelet aggregation.[76] Furthermore, the analysis of plasma samples from 20 patients with non-small cell lung cancer (NSCLC) and VTE, and 15 NSCLC patients without VTE, demonstrated differential expression of 5 proteins (SAA1, S100A8, lipopolysaccharide binding protein, haptoglobin, and lactate dehydrogenase B) in VTE patients.[77]

The platelet proteome

Platelets play a crucial role in cancer biology and CAT. Research has indicated that the platelet proteome exhibits variations based on the primary site of malignancy. For example, in a MS proteomics study involving patients with brain cancer, lung cancer, and healthy controls, while the platelet proteome remained unaltered in brain cancer, distinctive modifications and differential expression of proteins were observed in patients with lung cancer when compared to the healthy control group.[78] Furthermore, a separate study involving the platelet proteome of 9 individuals with diverse malignancies found that the platelet proteome was affected not only by the type of primary malignancy but also by the oncological treatment.[79]

Extracellular vesicles

Extracellular vesicles (EVs) facilitate the interaction between cancer cells, platelets, and the vascular system. In the context of CAT, cancer cells release EVs containing diverse bioactive substances, such as proteins, nucleic acids, and lipids. These EVs contribute to the hypercoagulability observed in cancer patients. Specifically, EVs released by cancer cells can activate platelets, inducing platelet aggregation and the formation of microthrombi. Furthermore, EVs have the potential to activate the coagulation cascade and hinder fibrinolysis, thereby amplifying the risk of thrombosis.[1,74]

Understanding the proteomic composition of these EVs is crucial for unraveling the molecular mechanisms underlying CAT. MS proteomics was applied to analyze EVs released from platelets in various triple-negative breast cancer (TNBC) cell lines. Results revealed that TNBC cell lines induced platelet aggregation, and the subsequent protein

profiling of extracellular vesicles released by platelets highlighted their active participation in this process. Notably, uPAR and PDGFRβ were identified as crucial contributors to the complex mechanism of extracellular vesicle-induced platelet aggregation.[80]

Comparing proteomic screening techniques in cancer-associated thrombosis

There is scant literature comparing proteomics screening techniques in CAT. A study compared multiple reaction monitoring (MRM) MS proteomics with conventional assays to evaluate levels of coagulation factors and fibrinolysis-related proteins. LC-MS was used to profile 31 proteins related to coagulation and fibrinolysis in 75 patients (25 with VTE, 25 with cancer and VTE, and 25 with healthy controls). All samples also underwent traditional antibody or activity-based assays. Both methods had a Pearson correlation of 0.77, indicating a good correlation, but MRM MS had a higher sensitivity, multiplicity, and performance.[81]

Limitations of proteomics in cancer-associated thrombosis

Proteomics has been applied in the context of thrombosis, revealing several promising biomarkers. However, despite these findings, markers have not been globally incorporated into clinical practice. The challenge in using these biomarkers can be attributed to several factors, including limited congruence among study outcomes, substantial variations in methods, protein sample preparation, sample types, and study populations. Proteomics studies in CAT exhibit significant heterogeneity, rendering direct comparisons between investigations challenging. Furthermore, the absence of external study validation adds complexity to the interpretation of results. The majority of these studies had a small sample size, impacting the statistical significance and general applicability of the findings. Subsequent analyses are warranted, with an emphasis on achieving greater methodological similarity across studies.

Conclusions

Proteomics enables the comprehensive analysis of protein alterations on a large scale, offering valuable insights for the timely diagnosis, accurate risk assessment, and effective treatment of VTE and CAT. The effective application of biomarkers to clinical practice requires the validation of studies using independent diverse cohorts. Artificial intelligence and machine learning methods are currently under investigation and represent promising tools in combination with proteomics for the identification of biomarkers in thrombosis.

Conflict of interest:

JIZ reports prior research funding from Incyte and Quercegen; consultancy for Sanofi, CSL Behring, and Calyx. RP reports consultancy for Merck Research. MJFT reports no conflicts of interest.

Availability of data and material:

not applicable, no new data were created or analyzed in this study.

References

1. Fernandes CJ, Morinaga LTK, Alves JL, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 2019;28:180119. [PubMed: 30918022]

2. Abdol Razak N, Jones G, Bhandari M, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers 2018;10:380. [PubMed: 30314362]

3. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet 2021;398:64–77. [PubMed: 33984268]

4. Sikkens JJ, Beekman DG, Thijs A, et al. How much overtesting is needed to safely exclude a diagnosis? A different perspective on triage testing using bayes' theorem. Arez AP, editor. PLOS ONE 2016;11:e0150891. [PubMed: 26939066]

5. Jacobs B, Obi A, Wakefield T. Diagnostic biomarkers in venous thromboembolic disease. J Vasc Surg Venous Lymphat Disord 2016;4:508–17. [PubMed: 27639008]

6. Yang P, Li H, Zhang J, Xu X. Research progress on biomarkers of pulmonary embolism. Clin Respir J.2021;15:1046–55. [PubMed: 34214256]

7. Eichinger S. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA 2003;290:1071. [PubMed: 12941680]

8. Palareti G, Legnani C, Cosmi B,V et al. Predictive value of D-Dimer Test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313–8. [PubMed: 12847064]

9. Avnery O, Martin M, Bura-Riviere A, et al. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med 2020;287:32–41. [PubMed: 31394000]

10. Di Minno MND, Calcaterra I, Papa A, et al. Diagnostic accuracy of D-Dimer testing for recurrent venous thromboembolism: A systematic review with meta-analysis. Eur J Intern Med 2021;89:39–47. [PubMed: 33933338]

11. Ay C, Vormittag R, Dunkler D, et al. D-Dimer and Prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study. J Clin Oncol 2009;27:4124–9. [PubMed: 19636003]

12. Khorana AA, DeSancho MT, Liebman H, et al. Prediction and prevention of cancer-associated thromboembolism. The Oncologist 2021;26:e2–7. [PubMed: 33274815]

13. Posch F, Riedl J, Reitter E, et al. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study. J Thromb Haemost 2020;18:1348–56. [PubMed: 32073229]

14. Riondino S, Ferroni P, Zanzotto F, et al. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers 2019;11:95. [PubMed: 30650562]

15. Helfer H, Skaff Y, Happe F, et al. Diagnostic approach for venous thromboembolism in cancer patients. Cancers 2023;15:3031. [PubMed: 37296993]

16. Gotta J, Gruenewald LD, Eichler K, et al. Unveiling the diagnostic enigma of D-dimer testing in cancer patients: Current evidence and areas of application. Eur J Clin Invest 2023;53:e14060. [PubMed: 37409393]

17. Niimi K, Nishida K, Lee C, et al. Optimal D-Dimer cutoff values for diagnosing deep vein thrombosis in patients with comorbid malignancies. Ann Vase Surg 2024;98:293–300.

18. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377–82. [PubMed: 20829374]

19. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern EmergMed 2012;7:291–2.

20. Bruinstroop E, Klok FA, Van De Ree MA, et al. Elevated d-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009;7:611–8. [PubMed: 19175498]

21. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna Prediction model. Circulation 2010;121:1630–6. [PubMed: 20351233]

22. Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014;11:140–56. [PubMed: 24419261]

23. Lindström S, Wang L, Smith EN, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood 2019;134:1645–57. [PubMed: 31420334]

24. Crous-Bou M, Harrington L, Kabrhel C. Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. Semin Thromb Hemost 2016;42:808–20. [PubMed: 27764878]

25. Letunica N, Van Den Helm S, McCafferty C, et al. Proteomics in Thrombosis and Hemostasis. Thromb Haemost 2022; 122: 1076–84. [PubMed: 34753192]

26. Zhang Z, Wu S, Stenoien DL, Paša-Toli L. High-Throughput Proteomics. Annu Rev Anal Chem 2014;7:427–54.

27. Howes JM, Keen JN, Findlay JB, Carter AM. The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease. Diab Vase Dis Res 2008;5:205–12.

28. Nanjappa V, Thomas JK, Marimuthu A, et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res 2014;42:D959–65. [PubMed: 24304897]

29. Ronsein GE, Pamir N, Von Haller PD, et al. Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. J Proteomics 2015;113:388–99. [PubMed: 25449833]

30. Edfors F, Iglesias MJ, Butler LM, Odeberg J. Proteomics in thrombosis research. Res Pract Thromb Haemost 2022;6:e12706. [PubMed: 35494505]

31. Aslam B, Basit M, Nisar MA, et al. Proteomics: Technologies and Their Applications. J Chromatogr Sci 2017;55:182–96. [PubMed: 28087761]

32. Uzozie AC, Aebersold R. Advancing translational research and precision medicine with targeted proteomics. J Proteomics 2018;189:1–10. [PubMed: 29476807]

33. Fu Q, Kowalski MP, Mastali M, et al. Highly Reproducible Automated Proteomics Sample Preparation Workflow for Quantitative Mass Spectrometry. J Proteome Res 2018; 17:420–8. [PubMed: 29083196]

34. Smith JG, Gerszten RE. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease. Circulation 2017;135:1651–64. [PubMed: 28438806]

35. Lubec G, Afjehi-Sadat L. Limitations and Pitfalls in Protein Identification by Mass Spectrometry. Chem Rev 2007;107:3568–84. [PubMed: 17645314]

36. Deutsch EW, Omenn GS, Sun Z,M et al. Advances and Utility of the Human Plasma Proteome. J Proteome Res 2021;20:5241–63. [PubMed: 34672606]

37. Zhang YX, Li JF, Yang YH, et al. Identification of haptoglobin as a potential diagnostic biomarker of acute pulmonary embolism. Blood Coagul Fibrinolysis 2018;29:275–81. [PubMed: 29538004]

38. Vormittag R, Vukovich T, Mannhalter C, et al. Haptoglobin phenotype 2-2 as a potentially new risk factor for spontaneous venous thromboembolism. Haematologica 2005;90:1557–61. [PubMed: 16266904]

39. Insenser M, Montes-Nieto R, Martínez-García MÁ, et al. Identification of reduced circulating haptoglobin concentration as a biomarker of the severity of pulmonary embolism: a nontargeted proteomic study. PloS One 2014;9.

40. Han B, Li C, Li H, et al. Discovery of plasma biomarkers with data-independent acquisition mass spectrometry and antibody microarray for diagnosis and risk stratification of pulmonary embolism. J Thromb Haemost 2021;19:1738–51. [PubMed: 33825327]

41. Jensen SB, Hindberg K, Solomon T, et al. Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics. J Thromb Haemost 2018;16:1763–74. [PubMed: 29964323]

42. Lundberg M, Eriksson A, Tran B, et al. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 2011;39:e102–e102. [PubMed: 21646338]

43. Brody E, Willis M, Smith J, et al. The use of aptamers in large arrays for molecular diagnostics. Mol Diagn 1999;4:381–8. [PubMed: 10671648]

44. Joshi A, Mayr M. In Aptamers They Trust: Caveats of the SOMAscan Biomarker Discovery Platform From SomaLogic. Circulation 2018;138:2482–5. [PubMed: 30524136]

45. Drobin K, Nilsson P, Schwenk JM. Highly Multiplexed antibody suspension bead arrays for plasma protein profiling. In: Drobin K, Bäckvall H, Lehtiö J (eds.). The low molecular weight proteome. New York, NY: Springer 2013:137–45.

46. Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat Commun 2021;12:6822. [PubMed: 34819519]

47. Bendes A, Dale M, Mattsson C, et al. Bead-Based assays for validating proteomic profiles in body fluids. In: Barderas R, LaBaer J, Srivastava S, editors. Protein Microarrays for Disease Analysis. New York, NY: Springer US 2021:65–78.

48. Wik L, Nordberg N, Broberg J, et al. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol Cell Proteomics 2021;20:100168. [PubMed: 34715355]

49. Ten Cate V, Prochaska JH, Schulz A, et al. Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. Blood 2021;137:2681–93. [PubMed: 33529319]

50. Nosaka M, Ishida Y, Kimura A, et al. Absence of IFN-γ accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice. J Clin Invest 2011;121:2911–20. [PubMed: 21646723]

51. Guo L, Liu M, Huang J, et al. Role of interleukin-15 in cardiovascular diseases. J Cell Mol Med 2020;24:7094–101. [PubMed: 32406586]

52. Memon AA, Sundquist K, PirouziFard M, et al. Identification of novel diagnostic biomarkers for deep venous thrombosis. Br J Haematol 2018;181:378–85. [PubMed: 29672822]

53. Purdy M, Obi A, Myers D, Wakefield T. P- and E- selectin in venous thrombosis and non-venous pathologies. J Thromb Haemost 2022;20:1056–66. [PubMed: 35243742]

54. Tang X, Zhang Z, Fang M, et al. Transferrin plays a central role in coagulation balance by interacting with clotting factors. Cell Res 2020;30:119–32. [PubMed: 31811276]

55. Kölmel S, Hobohm L, Käberich A, et al. Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension. Thromb Haemost 2019;119:1332–46. [PubMed: 31183846]

56. Khorana AA, Barnard J, Wun T, et al. Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Adv 2022;6:1212–21. [PubMed: 34807979]

57. Bruzelius M, Iglesias MJ, Hong MG, et al. PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood 2016;128:e59–66. [PubMed: 27742707]

58. Tannenberg P, Chang YT, Muhl L, et al. Extracellular retention of PDGF-B directs vascular remodeling in mouse hypoxia-induced pulmonary hypertension. Am J Physiol-Lung Cell Mol Physiol 2018;314:L593–605. [PubMed: 29212800]

59. Razzaq M, Iglesias MJ, Ibrahim-Kosta M, et al. An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism. Sci Rep 2021;11:14015. [PubMed: 34234248]

60. Greliche N, Germain M, Lambert JC, et al. A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis. BMC Med Genet 2013;14:36. [PubMed: 23509962]

61. Bussolino F, Valdembri D, Caccavari F, Serini G. Semaphoring vascular morphogenesis. Endothelium 2006;13:81–91. [PubMed: 16728327]

62. Kashiwagi H, Shiraga M, Kato H, et al. Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A. Blood 2005;106:913–21. [PubMed: 15831706]

63. Hardin M, Cho MH, McDonald ML, et al. A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease. Pharmacogenomics J 2016;16:326–35. [PubMed: 26503814]

64. Iglesias MJ, Sanchez-Rivera L, Ibrahim-Kosta M, et al. Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism. Nat Commun 2023;14:3280. [PubMed: 37286573]

65. Sanchez-Rivera L, Iglesias MJ, Ibrahim-Kosta M, et al. Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous thromboembolism and COVID-19 severity. Cardiovasc Med 2022. Available from: 10.1101/2022.04.20.22274046 (accessed on September 27th, 2023)

66. Lakhin AV, Tarantul VZ, Gening LV. Aptamers: problems, solutions and prospects. Acta Naturae 2013;5:34–43. [PubMed: 24455181]

67. Tala JA, Polikoff LA, Pinto MG, et al. Protein biomarkers for incident deep venous thrombosis in critically ill adolescents: An exploratory study. Pediatr Blood Cancer 2020;67:e28159. [PubMed: 31904170]

68. Petrera A, Von Toeme C, Behler J, et al. Multiplatform approach for plasma proteomics: complementarity of olink proximity extension assay technology to mass spectrometry-based protein profiling. J Proteome Res 2021;20:751–62. [PubMed: 33253581]

69. Katz DH, Robbins JM, Deng S, et al. Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods. Sci Adv 2022;8:eabm5164. [PubMed: 35984888]

70. Raffield LM, Dang H, Pratte KA, et al. Comparison of Proteomic Assessment Methods in Multiple Cohort Studies. PROTEOMICS 2020;20:1900278.

71. Faquih T, Mook-Kanamori DO, Rosendaal FR, et al. Agreement of aptamer proteomics with standard methods for measuring venous thrombosis biomarkers. Res Pract Thromb Haemost 2021;5:e12526. [PubMed: 34013156]

72. Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature 2023;622:348–58. [PubMed: 37794188]

73. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870–5. [PubMed: 17504985]

74. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factorbearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15:6830–40. [PubMed: 19861441]

75. Khorana AA, Connolly GC, Hagen F, et al. A proteomics-based approach to identifying mechanisms of cancer-associated thrombosis: potential role for immunoglobulins. Blood 2013;122:1127.

76. Cui M, Huang J, Zhang S, et al. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. Front Immunol. 2021;12:613530. [PubMed: 33841396]

77. Liu Y, Gao L, Fan Y, et al. Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry. Front Oncol 2023;13:1079719. [PubMed: 36874092]

78. Ercan H, Mauracher LM, Grilz E,H et al. Alterations of the platelet proteome in lung cancer: accelerated F13A1 and ER processing as new actors in hypercoagulability. Cancers 2021;13:2260. [PubMed: 34066760]

79. Walraven M, Sabrkhany S, Knol J, et al. Effects of cancer presence and therapy on the platelet proteome. Int J Mol Sci 2021;22:8236. [PubMed: 34361002]

80. McNamee N, De La Fuente LR, Santos-Martinez MJ, O'Driscoll L. Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation. BMC Cancer 2022;22:1023. [PubMed: 36171564]

81. Mohammed Y, Van Vlijmen BJ, Yang J, et al. Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer. Blood Adv 2017;1:1080–7. [PubMed: 29296750]

Mass-Spectrometry and Affinity-based Assays

Table 1.

Characteristic	Proteomics Technologies	
	Mass-Spectrometry	**Affinity-based Assays**
Protein Detection	Measures m/Q of peptide fragments.	Uses antibodies or aptamers that bind to proteins.
Protein Quantification	Provides absolute quantification of proteins, with an average of 10 peptides per protein.	Provides relative quantification but not absolute quantification of proteins.
Detection of Low Abundance Proteins	Lower sensitivity for the detection of low abundance proteins (<<10 ng/mL)	Higher sensitivity for the detection of low abundance proteins.
Specificity	High degree of specificity. Not restricted to a predefined set of targets. Suitable for use in diverse species and across a wide range of sample types.	Specificity varies according to the assay type and degree of cross-reactivity. Restricted to a predefined set of targets. Alteration of binding sites leads to a decrease in specificity.
Structural Insights and Proteoforms	Detects conformational changes in proteins, diverse protein isoforms, and post-translational modifications.	Unable to detect protein isoforms, post-translational modifications, and other proteoforms.
Throughput Capacity	Traditional MS methods have limited throughput capacity. Affinity enriched or affinity selection MS methods are used to overcome this challenge.	High throughput capacity using various affinity reagents.

Mass-to-charge ratio (m/Q), Mass spectrometry (MS)

Table 2.

Proteomic studies in Venous Thromboembolism

Author Year	Sample	Cohort	Comparative Groups	Methods	Results	Parameters (Cutoff, sensitivity, specificity, significance, correlation, HR)
Bruzelius et al. [33] 2016	Plasma	Patients from the VEBIOS and FARIVE studies	VEBIOS VTE (n=88) Healthy controls (n=85) *Verification study* FARIVE VTE (n=580) Healthy controls (n=589)	IC-MS ELISA Bead arrays 755 antibodies targeting 408 proteins.	VWF and PDGFB levels were significantly higher in patients with VTE. *Results were verified using patients from the FARIVE study	VWF (p <0 .001) PDGFB (p =0.002) Pearson's correlation between studies: VEBIOS:0.42 FARIVE:0.26
Jensen et al. [34] 2018	Plasma	Patients from the Tromsø Study	VTE (n=100) Healthy controls (n=100)	TMT LC-MS	Strongest biomarkers for the development of VTE: -Transthyretin -Protein Z (ProZ) -Protein/nucleic acid deglycase (DJ-1).	Transthyretin p=0.00015 ProZ p= 0.0018 DJ-1 p=0.0055
Razzaq et al. [39]	Plasma	1388 Patients with DVT with or without PE from the MARTHA and EOVT studies	MARTHA PE (n=95) DVT (n= 1105) DVT+PE (n=188) *Verification study* EOVT PE (n=143) DVT (n=196)	1.SBA in combination with Machine learning methods- ANN model. 2. Application of the LIME algorithm. 3. GWAS conducted on the LIME estimate.	PLXNA4 was identified as a susceptibility locus for isolated PE phenotype. Homozygote carriers for the rs1424597-A allele were more frequently observed in PE than in DVT patients. *Results were verified using patients from the EOVT study	GWAS on the LIME estimate (rs1424597): (p=5.3×10^{-7}) at the PLXNA4 locus. Homozygote carriers- isolated PE phenotype vs DVT: MARTHA (2% vs. 0.4%) p= 0.005 EOVT (3% vs. 0%) p = 0.013
Ten Cate et al. [40]	Plasma	532 Patients from the GMP-VTE study	GMP-VTE PE (n = 96) DVT (n = 160) DVT+PE (n = 276) *Verification study* Gutenberg Health study (n = 5778)	PEA 96-plex Olink panels (Cardiometabolic, cardiovascular II and III, Inflammation, and Immune response) Proteomics in combination with Machine learning: LASSO-regularized regression models.	Prognostic proteins for the development of primary isolated PE in comparison to DVT or DVT+PE: - Interferon-γ - GDNF -Interleukin-15Rα *Results were verified using patients from the Gutenberg Health study.	HR per SD increase - Interferon-γ HR (1.34 95% CI, 1.23-1.45; *P*<0.0001 -GDNF HR (0.40 5% CI, 0.29-0.55; *P*<0.0001) -Interleukin 15Rα HR (0.55 95% CI, 0.43-0.71; *P*<0.0001)
Han et al [43]	Plasma	Patients with PE and healthy controls from two case control studies	Discovery MS Analysis: High-risk PE (n= 3) Non-high-risk PE (n=6) Healthy controls (n=4) Antibody array Analysis High-risk PE (n= 10) Non-high-risk PE	MS Antibody array proteomic technology ELISA	Differentially expressed proteins in patients with PE/High-risk PE: -SAA1 -S100A8 -Tenascin-C(TNC) -Gelsolin -HRG *Results were verified using an independent cohort of 76 patients.	*AUC for PE diagnosis: P<0,05* -SAA1 Cut-off :1.26 μg/ml (AUC 0.882) -S100A8 Cut-off :1.19 μg/ml (AUC 0.788) -TNC Cut-off :12.62 μg/ml (AUC 0.795)

Author Year	Sample	Cohort	Comparative Groups	Methods	Results	Parameters (Cutoff, sensitivity, specificity, significance, correlation, HR)
			(n=10) Healthy controls (n=12) *Verification study* High-risk PE (n= 25) Non-high-risk PE (n=25) Healthy controls (n=26)			*AUC for High-risk PE diagnosis:* -S100A8 Cut-off :1.7 µg/ml (AUC 0.773) -TNC Cut-off :17 µg/ml (AUC 0.720)
Zhang et al [44]	Plasma	Patients with PE and matched healthy controls.	18 patients PE (n=9) Healthy controls: (n=9) *Verification study 48 patients* PE (n=24) Healthy controls (n=24)	2DE MALDI-TOF MS ELISA	Haptoglobin was overexpressed in the serum of PE patients. *Results were verified using an independent cohort of 48 patients	Haptoglobin cut-off: 256.74 mg/l AUC 0.764 (95% Cl, 0.622-0.906) P<0.01
Memon et al [47]	Plasma	357 patients with suspected DVT from a prospective multicenter (7 centers) management study in southern Sweden.	90 patients included Confirmed Acute DVT (n=45) Healthy matched controls (n=45)	PEA Olink Panel (Cardiovascular III)	Proteins significantly associated with VTE: -P-Selectin -TF pathway inhibitor TFPI) -VWF -Transferrin receptor protein 1(TR) -Osteopontin -Bleomycin hydrolase -ST2 protein	-P-Selectin AUC 0.84 (95%CI 0.76-0.92) p= 0.000001 -TFPI AUC 0.74 (95%CI 0.64-0.85) p= 0.00001 -VWF AUC 0.77 (95%CI 0.67-0.87) p= 0.00001 -TR AUC 0.78 (95%CI 0.69-0.88) p= 0.000001 -Osteopontin AUC 0.72 (95%CI 0.61-0.82) p= 0.0004 -Bleomycin hydrolase AUC 0.72 (95%CI 0.62-0.83) p= 0.0003 -ST2 protein AUC 0.71 (95%CI 0.60-0.83) p= 0.0007
Iglesias et al [48]	Plasma	Patients from the VEBIOS study	VTE (n=144) Healthy controls (n=140) *Verification studies:* -DFW-VTE -FARIVE	SBA LC-MS/MS	Complement factor H related 5 protein (CFHR5) was independently associated with VTE. *Results were verified with 4 independent cohorts from 4 large	Diagnosis of acute VTE associated with 1 SD increase of CFHR5 concentration: OR 2.54 (95%CI 1.52-4.66) *p* = 1.05E-03

Author Year	Sample	Cohort	Comparative Groups	Methods	Results	Parameters (Cutoff, sensitivity, specificity, significance, correlation, HR)
			-RETROVE -MARTHA		studies.	

2DE: Two-Dimensional gel electrophoresis, ANN: two hidden-layers artificial neural networks, DVT: Deep venous thrombosis, DFW-VTE: Swedish Karolinska Age Adjusted D-dimer study, FARIVE: French multicenter case-control study, GDNF: Glial cell-line derived Neurotrophic factor, GMP-VTE: The Genotyping and Molecular Phenotyping in Venous ThromboEmbolism study, GWAS: Genome wide association study, HR: Hazard Ratio, HRG: Histidine-rich glycoprotein, IC: Immunocapture, LC: Liquid chromatography, LIME: Local Interpretable Model-agnostic Explanations, MARTHA: Marseille Thrombosis Association study, MS: Mass spectroscopy, RETROVE: The Riesgo de Enfermedad Tromboembolica Venosa study. SAA1: serum amyloid A-1, SBA: Suspension bead array, SD: Standard Deviation, PE: Pulmonary embolism, TF: Tissue factor, TMT: tandem mass tag, VEBIOS: Venous thromboembolism Biomarker Study, VTE: Venous thromboembolism, VWF: Von Willebrand Factor

Table 3.

Potential Biomarkers in Cancer-Associated Thrombosis

Lung Cancer	
Proteins increased in VTE patients	IgV kappa light chain (76)
Proteins increased in non-VTE patients	Tetranectin (76)
Non-Small Cell Lung Cancer	
Proteins increased in VTE patients	SAA1, S100A8, LBP, HP and LDHB (78)
Pancreas Cancer	
Proteins increased in VTE patients	IgM Fc, immunoglobulin kappa chain variable region, Ig kappa chainVKIII-JK3, immunoglobulin heavy chain variable region, immunoglobulin kappa light chain variable region (76)
Proteins increased in non-VTE patients	Immunoglobulin kappa light chain variable region of different sequence (MW 8 kDa), phospholipase D (76)
Colorectal Cancer	
Proteins associated with increased risk of cancer-associated thrombosis	Angiotensinogen, apolipoprotein B100, CD5 antigen-like, and immunoglobulin heavy constant mu (85)
Platelet proteome in cancer patients	
Upregulated proteins	**Lung cancer:** Accelerated F13A1, Endoplasmic reticulum proteins (CALR, HSPA5, P4HB) (79) **Patients with cancer vs healthy controls:** FXIII, CALR (82)
Upregulated proteins	**Lung cancer:** Accelerated F13A1, Endoplasmic reticulum proteins (CALR, HSPA5, P4HB) (79) **Patients with cancer vs healthy controls:** FXIII, CALR (82)
Downregulated proteins	**Patients with cancer vs healthy controls:** Integrin alpha-IIb, albumin, gamma-enolase, and integrin beta 3 (82)

CALR: Calreticulin, F13A1: factor XIII 55 kDa fragment, FXIII: Coagulation Factor XIII, HP: Haptoglobin, HSPA5: Heat shock protein family A, LBP: Lipopolysaccharide binding protein, LDHB: Lactate dehydrogenase B, P4HB: Prolyl 4-hydroxylase subunit beta, SAA1: Serum Amyloid A1, S100A8: Calprotectin, VTE: Venous thromboembolism